ClinicalTrials.gg

Program

Magnesium Chloride

Also written as “Custodiol” and “Nalmefene + 0.94% MgCl2”.

Its studies are mostly in Opiate Overdose · Diabetes Mellitus, Type 1 · Aortic Valve Disease · Heart Failure · Coronary Artery Disease, led by 4 companies.

Furthest: phase 3, since Feb 14, 20147 company-led studies, 1 open or runningNext primary completion: Jan 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dr. F. Köhler Chemie41 open or runningphase 3since Feb 14, 2014Sep 29, 2011Jan 2027phase 2 · NCT06032195
Eli Lilly10 open or runningphase 1since Sep 28, 2021Sep 28, 2021none ahead
Knoa Pharma10 open or runningphase 1since Apr 15, 2026Apr 15, 2026none ahead
Relox Medical10 open or runningphase 3since Jun 30, 2009Jun 30, 2009none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 30, 2009First study: phase 3 study in StrokeNew to Relox MedicalRelox Medical · NCT00933868 · 81 enrolled · United States
  2. Sep 29, 2011Dr. F. Köhler Chemie's first study: phase 2 study in Coronary Artery DiseaseNew to Dr. F. Köhler ChemieDr. F. Köhler Chemie · NCT01444235 · 102 enrolled · Germany
  3. Feb 14, 2014Phase 3 study in Aortic Valve DiseaseDr. F. Köhler Chemie · NCT02098772 · 530 enrolled · Germany
  4. Aug 11, 2015Phase 3 study in Heart FailureDr. F. Köhler Chemie · NCT02869022 · 105 enrolled · Austria, Germany
  5. Sep 28, 2021Eli Lilly's first study: phase 1 study in Diabetes Mellitus, Type 1New to Eli LillyEli Lilly · NCT05067270 · 40 enrolled · Germany
  6. Aug 21, 2023Phase 2 study in Heart TransplantationDr. F. Köhler Chemie · NCT06032195 · 15 planned · Germany
  7. Apr 15, 2026Knoa Pharma's first study: phase 1 study in Opiate OverdoseNew to Knoa PharmaKnoa Pharma · NCT07543276 · 13 enrolled · United States

Ahead

  1. Jan 2027Primary completion: phase 2 study in Heart TransplantationDr. F. Köhler Chemie · NCT06032195

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 7 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07543276Opiate Overdose · United States1CompletedKnoa PharmaApr 3, 202613
NCT06032195Heart Transplantation · Germany2RecruitingDr. F. Köhler ChemieJan 202715
NCT05067270Diabetes Mellitus, Type 1 · Germany1CompletedEli LillyDec 6, 202140
NCT02869022Heart Failure · Austria, Germany3CompletedDr. F. Köhler ChemieSep 2, 2019105
NCT02098772Aortic Valve Disease · Germany3CompletedDr. F. Köhler ChemieNov 16, 2018530
NCT01444235Coronary Artery Disease · Germany2CompletedDr. F. Köhler ChemieMay 2012102
NCT00933868Stroke · United States3CompletedRelox MedicalMay 201081

How it is read

Names in the registry

  • “Custodiol”, 4 entries
  • “Nalmefene + 0.94% MgCl2”, 2 entries
  • “Magnesium Chloride”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.